# Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

> **NCT06375005** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 38 (estimated)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis

## Interventions

- **DRUG:** Telitacicept
- **DRUG:** Mycophenolate Mofetil

## Key facts

- **NCT ID:** NCT06375005
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-06
- **Primary completion:** 2027-01-06
- **Final completion:** 2027-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375005, "Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06375005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*